Abstract
This chapter is a set of recollections that would be difficult to document because they are based on my experience as a Food and Drug Administration (FDA) regulator and a pharmacologist with a special interest in cardiac repolarization. As is the common precedent, this is not related to considerations of antiarrhythmic drugs. Rather, this focus is upon drugs that have not been developed for the express purpose of modifying the behavior of cardiac ion channels, but as we all know many unexpectedly do.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Symposium on the QT Interval Prolongation: Is it harmful or beneficial? Edited by Joel Morganroth MD to be Published by Yorke Medical Publishers—August 26, 1993 as a monograph in the American Journal of Cardiology.
Gussak I, Brugada P, Brugada J, Wright RS, Kopecky SL, Chaitman BR, Bjerregaard P. Idiopathic short QT interval: a new clinical syndrome? Cardiology 2000;94:99–102.
Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation. 2004;109:30–35.
Schimpf R, Wolpert C, Bianchi F, Giustetto C, Gaita F, Bauersfeld U, Borggrefe M. Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol. 2003;14:1278–1279.
Glaser S, Steinbach M, Opitz C, Wruck U, Kleber FX. Torsades de pointes caused by Mibefradil. Eur J Heart Fail. 2001;3:627–630.
Browne KF, Zipes DP, Heger JJ, Prystowsky EN. Influence of the autonomic nervous system on the Q-T interval in man. Am J Cardiol. 1982;50:1099–1103.
Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implication for hear rate correction of the QT interval. Heart 2002;87:220–228
Food and Drug Administration and Health Canada. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Preliminary Concept paper, November 15, 2002 http://www.fda.gov/cder/workshop.htm#upcoming
Fenichel, RR, Malik, M, Antzelevitch, C, Sanguinetti, M, Roden, DM, Priori, S, et alDrug-induced Torsades de Pointes and implications for drug development. J Cardiovasc Electrophsiol 2004;15:1–21.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Lipicky, R.J. (2005). Cardiac Safety of Noncardiac Drugs. In: Morganroth, J., Gussak, I. (eds) Cardiac Safety of Noncardiac Drugs. Humana Press. https://doi.org/10.1007/978-1-59259-884-7_1
Download citation
DOI: https://doi.org/10.1007/978-1-59259-884-7_1
Publisher Name: Humana Press
Print ISBN: 978-1-58829-515-6
Online ISBN: 978-1-59259-884-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)